Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpe…
First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC
Preclinical data support potential to address ~45% of HNSCC tumors that harbor HRAS overexpression and/or PIK3CA mutation
SAN DIEGO, Oct. 26, 2022 (GLOBE NEWSWIRE) — Kura Oncology has recently reported preliminary proof of mechanism in a Phase 1/2 clinical trial of Tipifarnib Plus Alpelisib. This groundbreaking study marks the first demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent Head and Neck Squamous Cell Carcinoma (HNSCC).
Head and Neck Squamous Cell Carcinoma is a type of cancer that arises in the mucous membranes of the mouth, nose, and throat. Approximately 45% of HNSCC tumors harbor HRAS overexpression and/or PIK3CA mutation, making them particularly difficult to treat. However, the preclinical data for Tipifarnib Plus Alpelisib show promising results in targeting these specific genetic alterations.
Enrollment in the PIK3CA-dependent and HRAS-overexpression cohorts of the clinical trial is ongoing, with the hope of further validating the efficacy of this precision combination therapy.
How will this affect me?
As a patient with Head and Neck Squamous Cell Carcinoma, the results of Kura Oncology’s clinical trial could have a significant impact on your treatment options. If you harbor HRAS overexpression or PIK3CA mutation, Tipifarnib Plus Alpelisib may offer a more effective and durable clinical response compared to traditional therapies.
How will this affect the world?
The successful demonstration of precision combination therapies in treating PIK3CA-dependent HNSCC could pave the way for personalized cancer treatments in other types of solid tumors. This breakthrough has the potential to revolutionize the field of oncology and improve survival rates for patients with genetically complex cancers.
Conclusion
In conclusion, Kura Oncology’s preliminary proof of mechanism in the Phase 1/2 clinical trial of Tipifarnib Plus Alpelisib represents a major advancement in the treatment of Head and Neck Squamous Cell Carcinoma. The promising results of this study not only offer hope to patients with difficult-to-treat tumors but also have far-reaching implications for the future of precision medicine in oncology.
